AstraZeneca Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
AstraZeneca reported its Q2 2025 earnings with revenues of $14.5 billion, a 12% increase from Q2 2024, exceeding expectations by 2.6%. However, EPS of $1.58 fell short of estimates by 5.4%. Net income rose 27% to $2.45 billion, with a profit margin of 17%. Revenue is projected to grow 5.7% annually over the next three years, slightly above the UK Pharmaceuticals industry's forecast of 5.2%. AstraZeneca's shares have increased by 2.9% over the past week, but the company faces three warning signs that investors should consider.
AstraZeneca (LON:AZN) Second Quarter 2025 Results
Key Financial Results
- Revenue: US$14.5b (up 12% from 2Q 2024).
- Net income: US$2.45b (up 27% from 2Q 2024).
- Profit margin: 17% (up from 15% in 2Q 2024).
- EPS: US$1.58 (up from US$1.24 in 2Q 2024).
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
All figures shown in the chart above are for the trailing 12 month (TTM) period
AstraZeneca Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) missed analyst estimates by 5.4%.
Looking ahead, revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Pharmaceuticals industry in the United Kingdom.
Performance of the British Pharmaceuticals industry.
The company's shares are up 2.9% from a week ago.
Risk Analysis
You still need to take note of risks, for example - AstraZeneca has 3 warning signs we think you should be aware of.
